奥沙利铂、氟尿嘧啶联合紫杉醇治疗晚期食管癌的临床疗效

目的:探讨奥沙利铂、氟尿嘧啶联合紫杉醇治疗晚期食管癌的临床疗效。方法:将95例晚期食管癌患者按照随机数字表法分为两组，对照组（n=46）和观察组（n=49）。对照组采用奥沙利铂、氟尿嘧啶化疗，观察组采用奥沙利铂、氟尿嘧啶联合紫杉醇治疗。两组均以21d为1周期，3个周期后评价疗效。对比分析两组近期疗效、生活质量改善、毒副反应及随访1年中位生存时间。结果:观察组有效率（63.26%）显著高于对照组（41.30%），具有统计学差异（P＜0.05）。观察组KPS评分改善率显著高于对照组，而下降率显著低于对照组，均具有统计学差异（P＜0.05）。观察组恶心、呕吐发生率显著低于对照组，腹泻发生率显著高于对照组，具有统计学差异（P＜0.05）。两组白细胞减少、血小板减少、脱发、肝功能、肾功能、外周神经毒性比较不具有统计学差异（P＞0.05）。两组中位生存时间对比无统计学差异（P＞0.05）。结论:奥沙利铂、氟尿嘧啶联合紫杉醇治疗晚期食管癌的临床疗效显著。

Clinical efficacy of oxaliplatin,fluorouracil in combination with paclitaxel in the treatment of advanced esophageal cancer

Objective:To evaluate clinical efficacy of oxaliplatin,fluorouracil plus paclitaxel in advanced esopha-geal cancer treatment. Methods:All 95 patients with advanced esophageal cancer were randomly divided into two groups,control group(n = 46)and observation group(n = 49). Control group was treated with oxaliplatin,fluorouracil chemotherapy,observation group oxaliplatin,fluorouracil in combination with paclitaxel therapy. Results:The response rate in observation group(63. 26% )was significantly higher(41. 30% ),and has a statistically significant difference (P < 0. 05). KPS score improved in observation group was significantly higher,while the decline was significantly low-er than the control group,and both had significant differences(P < 0. 05). Observation group nausea and vomiting were significantly lower than the control group,while the incidence of diarrhea was significantly higher,and had statis-tically significant difference(P < 0. 05). In two groups leukopenia,thrombocytopenia,alopecia,liver function,kidney function,peripheral neurotoxicity had no statistically significant difference(P > 0. 05). In two groups median survival time had no significant difference(P > 0. 05). Conclusion:Oxaliplatin,fluorouracil plus paclitaxel clinical efficacy in patients with advanced esophageal cancer was significantly.